Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

Clavis Pharma Provides Update on Pivotal LEAP Trial with CP-4126

Published: Monday, October 22, 2012
Last Updated: Monday, October 22, 2012
Bookmark and Share
64% of the 360 patients enrolled in the study are hENT1-low.

Clavis Pharma ASA reports that Clovis Oncology, its partner for CP-4126 (also known as CO-101), has been informed by the Independent Data Monitoring Committee that 64% of the 360 patients enrolled into the pivotal LEAP study were classified as hENT1-low.

The hENT1-low patients comprise the target population in which the primary survival endpoint of the LEAP trial, which is evaluating CP-4126 in metastatic pancreatic cancer patients, will be assessed.

The final hENT1 classification is in line with the previously reported results, announced in January 2012, and those from retrospective analyses (the 002 study) of hENT1 expression in pancreatic cancer tissues, that approximately two thirds of metastatic pancreatic patients are likely to be hENT1-low.

Studies have shown that hENT1-low patients derive little or no benefit from standard gemcitabine therapy (refs 1-4).

The final size of the hENT1-low population among the 360 patients in the fully enrolled LEAP study also confirms that the trial is well-powered.

Top-line results from the trial are expected to be announced in the fourth quarter of 2012, and if positive, regulatory filings are anticipated in the US and Europe in mid-2013.

Olav Hellebø, Clavis Pharma CEO, said: "The size of the hENT1-low population for the primary endpoint analysis in the LEAP study confirms our belief that there is a significant proportion of pancreatic cancer patients who are not likely to benefit from standard gemcitabine therapy and that CP-4126 could provide a new treatment option for these patients. We look forward to results of the LEAP study later in 2012 with great anticipation.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,600+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Promising Efficacy from Elacytarabine/idarubicin Combination in Phase II AML Study
Data presented at the American Society of Hematology annual meeting.
Monday, December 10, 2012
Clavis Pharma Completes Patient Recruitment in Phase III CLAVELA Study in AML Patients
Top-line data are expected to be available in Q1 2013.
Thursday, December 06, 2012
Clavis Pharma Announces Results of the LEAP Study of CP-4126 in Metastatic Pancreatic Cancer
Clavis Pharma continues to focus on elacytarabine and its Phase III CLAVELA study in leukaemia patients.
Monday, November 19, 2012
Clavis Pharma Announces Size of Initial hENT1-low Population in Pivotal LEAP Trial with CP-4126
65 percent of the initial 250 patients enrolled in the study are hENT1-low.
Monday, March 05, 2012
Clavis Pharma - Update Regarding Phase III CLAVELA Trial
Top line results are expected in the first quarter of 2013, one quarter delayed.
Tuesday, January 17, 2012
Clovis Oncology Expands the Observational Study to Determine Patient Stratification in Pivotal LEAP Clinical Trial with CP-4126
New, improved hENT1 biomarker assay developed.
Monday, January 02, 2012
Clavis Pharma Announces the Completion of Study 002
Low hENT1 cut-off level determined for pivotal LEAP study of CP-4126 in patients with pancreatic cancer.
Friday, October 28, 2011
Clavis Pharma Second Quarter and First Half Report 2011
Clavis Pharma and Clovis Oncology expanded the LEAP study, evaluating CP-4126 vs. gemcitabine in pancreatic cancer patients.
Friday, August 26, 2011
Clavis Pharma Expands Phase III CLAVELA Study in Patients With Acute Myeloid Leukaemia
Top line data are now expected to be available in Q4 2012.
Friday, August 26, 2011
Clavis Pharma’s CP-4126 Enters New Phase II Clinical Trial in Pancreatic Cancer Patients
The trial will investigate the use of CP-4126 as a 2nd line treatment for advanced, metastatic pancreatic cancer in patients refractory to 1st line gemcitabine treatment.
Friday, February 04, 2011
Clavis Pharma and Clovis Oncology Extend Partnership and Sign new $205 Million Deal
Partnership is aimed for the development and commercialization of anti-cancer agent CP-4126 in Asia and rest of the World.
Friday, November 12, 2010
Scientific News
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Antibody Treatment Efficacious in Psoriasis
An experimental, biologic treatment, brodalumab, achieved 100 percent reduction in psoriasis symptoms in twice as many patients as a second, commonly used treatment, according to the results of a multicenter clinical trial led by Mount Sinai researchers.
Scientists Test New Gene Therapy for Vision Loss from a Mitochondrial Disease
NIH-funded study shows success in targeting mitochondrial DNA in mice.
HIV Patients Should Be Included in Early Clinical Trials of Anti-TB Drugs
Tuberculosis is the number one cause of death in HIV-infected patients in Africa and a leading cause of death in this population worldwide.
Multi-Gene Test Enables Some Breast Cancer Patients to Safely Avoid Chemotherapy
A major study is providing the best evidence to date that a 21-gene test done on the tumor can identify breast cancer patients who can safely avoid chemotherapy.
Low Dose Beta-Blockers As Effective As High Dose After a Heart Attack?
Heart attack patients live as long – or even longer – on one-quarter the suggested dose.
Antidepressants Plus Blood-Thinners Slow Down Brain Cancer
EPFL scientists have found that combining antidepressants with anticoagulants slows down brain tumors (gliomas) in mice.
Old Drug Performs New Tricks
Cambridge-led research reveals the powers of a "wonder drug" that has lain under the noses of doctors for 50 years.
Electronic Reminders Keep TB Patients on Track With Medication In China
Giving electronic reminders to tuberculosis (TB) patients in China can reduce the amount of medication doses they miss by half, according to new research.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,600+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos